Manufacturing Assets For Sale

Elizabeth, NJ

Emerging Clinical Diagnostics Laboratory – Built for Scale | $4–$5M Revenue Growth Potential This is a rare opportunity to acquire a fully credentialed clinical medical laboratory in its early growth stage, strategically positioned to scale to $4–$5 million in annual revenue within the next 24 months under focused business development and payer expansion. Importantly, this is not a startup concept — it is an operational, credentialed lab platform. The infrastructure, licensing, equipment, and compliance foundation are already in place. Replicating this build-out from scratch would conservatively exceed $4 million in capital investment, making this a true replacement-cost opportunity with substantial upside. Business Overview This clinical laboratory provides a wide range of diagnostic testing services used by healthcare providers to diagnose, monitor, and screen for health conditions. The lab is: Registered with an active NPI (National Provider Identifier) Operating under CLIA certification Approved to perform regulated clinical laboratory testing The platform is structured for expansion, not stabilization — presenting a growth-oriented acquisition opportunity. Services & Capabilities The lab currently offers a broad testing menu, including: Genetic and molecular diagnostics Routine clinical testing Clinical toxicology Allergy testing COVID-19 testing Regulatory listings allow testing across multiple disciplines, including: Bacteriology Clinical chemistry Immunology (serology) Endocrinology Hematology Toxicology Urinalysis Virology This diversified testing capability supports scalability across multiple provider verticals. Clinical Credentials The laboratory team includes: Board-certified pathologists Ph.D.-level professionals with credentials in molecular diagnostics Qualified clinical laboratory personnel The lab emphasizes competitive turnaround times and flexible provider ordering/reporting systems, creating a scalable provider-facing platform. Location & Market Located in Central New Jersey, servicing healthcare providers throughout New York and New Jersey — two of the most regulated and high-value healthcare markets in the country. Growth Opportunity- ASSET SALE This lab is in its infancy operationally but fully built structurally. Key growth drivers include: Expansion of provider network Increased specimen volume Strategic payer contracting Sales force deployment Targeted specialty testing expansion With proper capitalization and business development, the platform is positioned for significant near-term revenue growth. Ideal Buyer Strategic laboratory operators Healthcare investors Private equity groups Physician groups seeking vertical integration Healthcare consolidators Confidential offering. Financials, payer mix, equipment schedules, and regulatory documentation available upon NDA.

MY

Both plants are at the same location in Far-East Asia. One being a Hydrogen plant, and one being a CO2 plant. Both are unused, and fully containerized Hydrogen (H2) and Carbon Dioxide (CO2) plants are designed to deliver efficient and sustainable industrial solutions. These modular units are perfect for businesses seeking a reliable and cost-effective way to meet production needs without extensive installation or downtime. These containerized plants are ideal for companies prioritizing flexibility, scalability, and sustainability. Whether your company is expanding capacity or starting a new project, these units provide a seamless, hassle-free solution tailored to the industrial requirements. Hydrogen by Steam Reforming With the HC process, high-purity hydrogen is produced by steam reforming of a hydrocarbon combined with a PSA purification step. The feed is mixed with a split stream of hydrogen and then preheated In the heat exchanger prior to passing a sulfur removal. The feed is then mixed with superheated steam. Whilst passing the catalyst in the reformer tubes, the mixture of water vapor and feed is converted into syngas consisting of H2, CO, CO2, H2O, and CH4. The hot syngas pass the heat exchanger in which the main part of sensible heat is utilized, thus adjusting the temperature of the syngas for the subsequent CO-shift. In the cooler following the CO-shift, the syngas are cooled to ambient temperatures, whilst simultaneously water vapor is condensed and subsequently separated. The syngas now pass the molecular sieve PSA purification unit where the H2 is isolated to the specified purity. The reformer is fired by a high-velocity burner which burns fuel and tail gas.